Engineered mRNA Delivery Systems for Biomedical Applications
Source abstract
Abstract
Abstract Messenger RNA (mRNA)‐based therapeutic strategies have shown remarkable promise in preventing and treating a staggering range of diseases. Optimizing the structure and delivery system of engineered mRNA has greatly improved its stability, immunogenicity, and protein expression levels, which has led to a wider range of uses for mRNA therapeutics. Herein, a thorough analysis of the optimization strategies used in the structure of mRNA is first provided and delivery systems are described in great detail. Furthermore, the latest advancements in biomedical engineering for mRNA technology, including its applications in combatting infectious diseases, treating cancer, providing protein replacement therapy, conducting gene editing, and more, are summarized. Lastly, a perspective on forthcoming challenges and prospects concerning the advancement of mRNA therapeutics is offered. Despite these challenges, mRNA‐based therapeutics remain promising, with the potential to revolutionize disease treatment and contribute to significant advancements in the biomedical field.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Rheumatology and Immunology Nanjing Drum Tower Hospital School of Biological Science and Medical Engineering Southeast University Nanjing 210096 China
Institute of Organoids on Chips Translational Research Henan Academy of Sciences Zhengzhou 450009 China
Department of Endocrinology Zhongda Hospital School of Medicine Southeast University Nanjing 210009 China
Funding
National Key Research and Development Program of China · National Natural Science Foundation of China · Nanjing Medical Science and Technique Development Foundation · Basic and Applied Basic Research Foundation of Guangdong Province · Shenzhen Fundamental Research Program
References (100+)
Show source-provided references
1. 10.1038/s41586-020-2622-010.1038/s41586-020-2622-0 ↗
2. 10.1126/scitranslmed.abm330210.1126/scitranslmed.abm3302 ↗
3. 10.1126/sciadv.abq350010.1126/sciadv.abq3500 ↗
4. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
5. 10.1038/s41565-023-01347-w10.1038/s41565-023-01347-w ↗
6. 10.1177/205101361350872910.1177/2051013613508729 ↗
7. 10.1038/s41392-022-01007-w10.1038/s41392-022-01007-w ↗
8. 10.1038/s41467-021-21037-210.1038/s41467-021-21037-2 ↗
9. 10.1016/j.bioactmat.2020.07.00310.1016/j.bioactmat.2020.07.003 ↗
10. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
11. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
12. 10.1038/s41587‐023‐01774‐z10.1038/s41587‐023‐01774‐z ↗
13. 10.1038/s41551-023-01030-410.1038/s41551-023-01030-4 ↗
14. 10.1016/j.omtn.2022.09.01010.1016/j.omtn.2022.09.010 ↗
15. 10.1016/j.cell.2017.02.01710.1016/j.cell.2017.02.017 ↗
16. 10.1016/j.cytogfr.2007.06.01610.1016/j.cytogfr.2007.06.016 ↗
17. 10.1038/s41591-022-02061-110.1038/s41591-022-02061-1 ↗
18. 10.1038/nbt.380210.1038/nbt.3802 ↗
19. 10.1146/annurev-biochem-080411-12403610.1146/annurev-biochem-080411-124036 ↗
20. 10.1016/j.sbi.2016.06.00110.1016/j.sbi.2016.06.001 ↗
21. O. V.Sergeeva V. E.Koteliansky T. S.Zatsepin 2016 81 709.10.1134/S0006297916070075 ↗
22. 10.1016/j.biotechadv.2023.10813010.1016/j.biotechadv.2023.108130 ↗
23. 10.1016/j.fmre.2023.02.02210.1016/j.fmre.2023.02.022 ↗
24. 10.1016/j.ajic.2023.02.00510.1016/j.ajic.2023.02.005 ↗
25. 10.1016/j.drudis.2022.10345810.1016/j.drudis.2022.103458 ↗
26. 10.1016/j.apsb.2022.11.02610.1016/j.apsb.2022.11.026 ↗
27. 10.1016/j.smaim.2022.11.00110.1016/j.smaim.2022.11.001 ↗
28. 10.1016/j.matt.2022.03.00610.1016/j.matt.2022.03.006 ↗
29. 10.1016/j.addr.2020.07.00110.1016/j.addr.2020.07.001 ↗
30. 10.1016/j.jconrel.2021.08.06110.1016/j.jconrel.2021.08.061 ↗
31. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
32. 10.1016/j.jconrel.2009.11.00810.1016/j.jconrel.2009.11.008 ↗
33. 10.7150/thno.691410.7150/thno.6914 ↗
34. 10.1038/nrg376310.1038/nrg3763 ↗
35. 10.1016/j.ajps.2022.05.00310.1016/j.ajps.2022.05.003 ↗
36. 10.1016/j.cellimm.2020.10414310.1016/j.cellimm.2020.104143 ↗
37. 10.3390/pharmaceutics1302020610.3390/pharmaceutics13020206 ↗
38. 10.1016/0006-291X(61)90155-310.1016/0006-291X(61)90155-3 ↗
39. 10.1038/190576a010.1038/190576a0 ↗
40. 10.1038/274921a010.1038/274921a0 ↗
41. 10.1038/255033a010.1038/255033a0 ↗
42. 10.1038/233177a010.1038/233177a0 ↗
43. 10.1126/science.169091810.1126/science.1690918 ↗
44. 10.1038/nbt.250110.1038/nbt.2501 ↗
45. 10.1097/CJI.0b013e3181a0006810.1097/CJI.0b013e3181a00068 ↗
46. 10.1089/1043034995001676210.1089/10430349950016762 ↗
47. 10.1172/JCI021436410.1172/JCI0214364 ↗
48. 10.1158/0008-5472.CAN-10-069910.1158/0008-5472.CAN-10-0699 ↗
49. 10.1038/s41586-021-03275-y10.1038/s41586-021-03275-y ↗
50. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
51. 10.1007/s41061-017-0106-y10.1007/s41061-017-0106-y ↗
52. 10.1093/nar/gkw55110.1093/nar/gkw551 ↗
53. 10.1039/C8OB01720D10.1039/C8OB01720D ↗
54. Stepinski J. · RNA · 2001 · 7 · 1486
55. 10.1016/j.addr.2020.12.01410.1016/j.addr.2020.12.014 ↗
56. 10.1042/BJ2009135210.1042/BJ20091352 ↗
57. 10.1016/j.antiviral.2021.10514210.1016/j.antiviral.2021.105142 ↗
58. 10.1016/j.virusres.2014.10.00810.1016/j.virusres.2014.10.008 ↗
59. 10.1038/nature0948910.1038/nature09489 ↗
60. 10.1261/rna.70130710.1261/rna.701307 ↗
61. Strenkowska M. · Nucleic Acids Res. · 2016 · 44 · 9578
62. 10.1016/j.biomaterials.2017.11.03410.1016/j.biomaterials.2017.11.034 ↗
63. 10.1038/nature1432110.1038/nature14321 ↗
64. 10.1038/nrm283810.1038/nrm2838 ↗
65. 10.1155/2012/47573110.1155/2012/475731 ↗
66. 10.1016/S0968-0004(03)00051-310.1016/S0968-0004(03)00051-3 ↗
67. 10.1038/nbt.285110.1038/nbt.2851 ↗
68. 10.1093/nar/gki101210.1093/nar/gki1012 ↗
69. 10.1093/dnares/dsn03010.1093/dnares/dsn030 ↗
70. 10.1089/ten.tea.2017.048510.1089/ten.tea.2017.0485 ↗
71. Schrom E. · Mol. Ther. · 2017 · 7 · 350
72. 10.3390/vaccines801012310.3390/vaccines8010123 ↗
73. 10.1016/j.cej.2023.14315210.1016/j.cej.2023.143152 ↗
74. 10.1002/adma.20200445210.1002/adma.202004452 ↗
75. 10.1038/s41587-019-0164-510.1038/s41587-019-0164-5 ↗
76. 10.1038/nbt.330010.1038/nbt.3300 ↗
77. 10.1038/s41598-019-51984-210.1038/s41598-019-51984-2 ↗
78. 10.1016/j.molmed.2014.09.00310.1016/j.molmed.2014.09.003 ↗
79. 10.1016/j.cell.2015.02.02910.1016/j.cell.2015.02.029 ↗
80. 10.1016/S1473-3099(21)00677-010.1016/S1473-3099(21)00677-0 ↗
81. 10.1038/s41541-021-00311-w10.1038/s41541-021-00311-w ↗
82. 10.1038/s41586-021-04231-610.1038/s41586-021-04231-6 ↗
83. 10.1038/s41467-021-24339-710.1038/s41467-021-24339-7 ↗
84. 10.1038/sj.gt.330218410.1038/sj.gt.3302184 ↗
85. 10.1093/bioinformatics/17.suppl_1.S9710.1093/bioinformatics/17.suppl_1.S97 ↗
86. 10.1038/s41586-023-06127-z10.1038/s41586-023-06127-z ↗
87. 10.1016/j.immuni.2005.06.00810.1016/j.immuni.2005.06.008 ↗
88. 10.1093/nar/gkq34710.1093/nar/gkq347 ↗
89. 10.1038/mt.2008.20010.1038/mt.2008.200 ↗
90. 10.3390/vaccines901006510.3390/vaccines9010065 ↗
91. 10.1038/nbt.173310.1038/nbt.1733 ↗
92. 10.1016/j.jconrel.2015.08.05110.1016/j.jconrel.2015.08.051 ↗
93. 10.1016/j.stem.2010.08.01210.1016/j.stem.2010.08.012 ↗
94. 10.1016/j.semcdb.2014.05.01810.1016/j.semcdb.2014.05.018 ↗
95. 10.1016/j.tcb.2018.11.00210.1016/j.tcb.2018.11.002 ↗
96. 10.1038/s41592-019-0503-y10.1038/s41592-019-0503-y ↗
97. 10.1042/BST2014011110.1042/BST20140111 ↗
98. 10.1002/wrna.123310.1002/wrna.1233 ↗
99. 10.1006/jmbi.1996.006510.1006/jmbi.1996.0065 ↗
100. 10.1016/j.cell.2019.04.01310.1016/j.cell.2019.04.013 ↗